Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • HBV
  • NASH - Nonalcoholic Steatohepatitis
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Currently, chronic hepatitis B virus (HBV) infection therapies are limited to pegylated interferon alpha (Peg-IFN?) and nucleos(t)ide analogues (NUCs), alone or in combination. Even though they can reduce viremia level (circulating viral load), the loss of HBs antigen (HBsAg), which indicates functi...

Currently, chronic hepatitis B virus (HBV) infection therapies are limited to pegylated interferon alpha (Peg-IFN?) and nucleos(t)ide analogues (NUCs), alone or in combination. Even though they can reduce viremia level (circulating viral load), the loss of HBs antigen (HBsAg), which indicates functional clearance of the virus, is achieved in less than 10% of cases. The absence of curative treatment to eliminate the infection justifies the need to define new targets and to develop new therapeutic strategies, with an immuno-therapeutic component. Chronic HBV infection is associated with persistent and virally-induced immune deficiency. The immunological control of the infection seems essential to the functional clearance of the virus. The restoration of appropriate immune responses against the virus could prove to be a promising therapeutic strategy. However, the mechanisms in which HBV modulates immune function is still poorly understood. Dendritic cells (DCs) have an essential role in immunity. They play a central role in the induction and regulation of immune responses. Also, they play a particularly crucial role in the induction and orientation of antiviral immunity due to their unique properties at the interface between innate and acquired immune responses. In several chronic viral infections, DCs appear defective. The immune responses induced in the early stages of infection seem to be a crucial guide on the progression of the infection into the resolution or the chronicity. Objective of the investigators is to better understand the virus escape mechanism from immune control, particularly, to determine the mechanisms in which the virus modulates the functions of DCs, crucial for the subsequent orientation of antiviral immune responses, to define the molecular mechanisms of this inhibition and their consequences on the antiviral effectors functions, in order to propose new immunotherapeutic approaches that compromise the chronicity of the infection and treat the infection permanently and definitively. Lastly, the investigators have shown that there are functional impairments in plasmacytoid DCs (pDCs) in patients with chronic hepatitis B, associated with a lack of cytotoxic activity of NK cells. The Subverting of pDCs in HBV patients could be related to IP-10 and HBsAg and HBeAg antigens or other viral components (infectious particles or circulating HBcAg). In addition, HBV was able to inhibit the production of IFN? by pDCs from healthy individuals in response to TLR9 agonists, by the presence of inhibitory CpG sequences in its genome. This mechanism would allow the virus to actively escape the innate immune response mounted by pDCs. Recently, investigators have found an alteration of lectin C-type receptor (CLR) expression on pDCs of HBV patients compared to healthy donors as well as a phenotypic and functional modulation in the 3 major subtypes of DCs (mDCs BDCA1 +, pDCs BDCA2 + and mDCs BDCA3 +) in the context of chronic HBV infection. These major subversions of DCs, crucial cells for subsequent orientation of antiviral immune responses, support the hypothesis that HBV might deflect immunity by impacting these cells. In this clinical trial, investigators would like to pursue their research to better understand the functional impairments of DCs in chronic HBV infection, by defining if the virus is able to bind to the CLRs of DCs to modulate their functions, and by defining the role of viral components and the molecular mechanisms of DCs modulation by HBV. This project should provide a better understanding of the mechanisms of the immune response orientation by HBV and the immunological control of the infection, and thus propose new immunotherapeutic strategies based on the restoration of DC functions by releasing of virally-induced inhibitions, compromising the infection chronicity

Tracking Information

NCT #
NCT03753308
Collaborators
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Etablissement Français du Sang
Investigators
Principal Investigator: Vincent LEROY, Pr CHU Grenoble Alpes